Discovery of an Orally Efficacious Pyrazolo[3,4- d ]pyrimidine Benzoxaborole as a Potent Inhibitor of Cryptosporidium
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02805 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Makafui Gasonoo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, Missouri 63103, United States. Hauptthemen laut MEDLINE: Pyrimidines, Cryptosporidiosis, Boron Compounds, Pyrazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Cryptosporidiosis is a diarrheal disease caused by the parasite Cryptosporidium resulting in over 100,000 deaths annually. Here, we present a structure-activity relationship study of the benzoic acid position (R6) of pyrazolo[3,4-d]pyrimidine lead SLU-2815 (1), an inhibitor of parasite phosphodiesterase CpPDE1, resulting in the discovery of benzoxaborole SLU-10906 (63) as a benzoic acid bioisostere. Benzoxaborole 63 is 10-fold more potent than 1 against the parasite in a cell-based infection model (EC50 = 0.19 μM) and non-cytotoxic. Furthermore, 63 has a fast rate of parasite-killing and is orally efficacious in a Cryptosporidium mouse infection model (50 mg/kg BID), although relapse was observed 7 days post-drug treatment. The partial selectivity profile versus human phosphodiesterases is preserved with the benzoxaborole motif and represents an important feature to improve in future optimization. Benzoxaborole 63 represents an important advance toward the optimization of the pyrazolo[3,4-d]pyrimidine series and the identification of a drug to treat cryptosporidiosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, School of Science and Engineering, Saint Louis University, Saint Louis, Missouri 63103, United States.
- Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont 05401, United States.
- Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, Missouri 63104, United States.
- Institute for Drug and Biotherapeutic Innovation, Saint Louis University, St. Louis, Missouri 63103, United States.
ORCID-Profile: Soumitra Guin, Marvin J Meyers
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Gasonoo, M., Guin, S., Teixeira, J. E., Oboh, E., Gokanapalle, A., Miller, P., Oliva, J., Sverdrup, F. M., Huston, C. D., & Meyers, M. J. (2025). Discovery of an Orally Efficacious Pyrazolo[3,4- d ]pyrimidine Benzoxaborole as a Potent Inhibitor of Cryptosporidium. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02805
Vancouver
Gasonoo M, Guin S, Teixeira JE, Oboh E, Gokanapalle A, Miller P, et al. Discovery of an Orally Efficacious Pyrazolo[3,4- d ]pyrimidine Benzoxaborole as a Potent Inhibitor of Cryptosporidium. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02805
BibTeX
@article{Gasonoo2025,
author = {Gasonoo, Makafui and Guin, Soumitra and Teixeira, José E and Oboh, Edmund and Gokanapalle, Anusha and Miller, Peter and Oliva, Jonathan and Sverdrup, Francis M and Huston, Christopher D and Meyers, Marvin J},
title = {Discovery of an Orally Efficacious Pyrazolo[3,4- d ]pyrimidine Benzoxaborole as a Potent Inhibitor of Cryptosporidium},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02805}
}
EUVIMED